Company logo

NVTA - Invitae Corporation

NYSE -> Healthcare -> Diagnostics & Research
San Francisco, United States
Type: Equity

NVTA price evolution
NVTA
(in millions $) 30 Sep 2023 30 Jun 2023 31 Mar 2023 31 Jan 2023
Current assets
Cash $168.11 $233.27 $171.23 $267.52
Short term investments $96.57 $102.38 $217.5 $289.61
Net receivables $82.51 $85.61 $85.59 $96.15
Inventory $21.63 $20.81 $19.07 $30.39
Total current assets $378.4 $451.23 $504.27 $693.13
Long term investments
Property, plant & equipment $127.08 $166.81 $173.5 $215.29
Goodwill & intangible assets $873.92 $981.89 $1012.55
Total noncurrent assets $156.72 $1071.81 $1187.39 $1260.99
Total investments $96.57 $102.38 $217.5 $289.61
Total assets $535.12 $1523.04 $1691.66 $1954.12
Current liabilities
Accounts payable $25.18 $23.07 $11.9 $13.98
Deferred revenue
Short long term debt $48.51 $20.95 $93.15 $19.72
Total current liabilities $158.42 $151.97 $190.18 $108.09
Long term debt $1459.87 $1561.42 $1526.68 $1596.9
Total noncurrent liabilities $1460.1 $1571.86 $1538.14 $1744.19
Total debt $1508.38 $1582.37 $1619.83 $1751
Total liabilities $1618.52 $1723.83 $1728.32 $1852.28
Shareholders' equity
Retained earnings -$6169.94 -$5227.84 -$5021.32 -$4829.14
Other shareholder equity $25.38 $8.91 -$0.11 -$0.08
Total shareholder equity -$1083.4 -$200.79 -$36.66 $101.84
(in millions $) 31 Jan 2023 31 Dec 2021 31 Dec 2020 31 Dec 2019
Current assets
Cash $267.52 $933.52 $131.48 $157.57
Short term investments $289.61 $122.12 $229.19 $240.44
Net receivables $96.15 $66.23 $47.72 $32.54
Inventory $30.39 $33.52 $32.03 $6.65
Total current assets $693.13 $1178.81 $453.93 $442.4
Long term investments
Property, plant & equipment $215.29 $235.88 $111.21 $74.39
Goodwill & intangible assets $1012.55 $3471.05 $2845.47 $251.95
Total noncurrent assets $1260.99 $3740.76 $2976.55 $339.2
Total investments $289.61 $122.12 $229.19 $240.44
Total assets $1954.12 $4919.57 $3430.49 $781.6
Current liabilities
Accounts payable $13.98 $21.13 $25.2 $10.32
Deferred revenue
Short long term debt $19.72 $16.52 $10.48 $6.72
Total current liabilities $108.09 $144.09 $121.75 $81.86
Long term debt $1596.9 $1707.58 $439.65 $312.1
Total noncurrent liabilities $1744.19 $1797.07 $1332.45 $320.1
Total debt $1751 $1724.1 $450.14 $318.83
Total liabilities $1852.28 $1941.17 $1454.19 $401.96
Shareholders' equity
Retained earnings -$4829.14 -$1722.85 -$1360.85 -$758.68
Other shareholder equity -$0.08 -$0.01 $0 -$0.01
Total shareholder equity $101.84 $2978.4 $1976.29 $379.64
(in millions $) 30 Sep 2023 30 Jun 2023 31 Mar 2023 31 Dec 2022
Revenue
Total revenue $121.24 $120.53 $117.36 $122.45
Cost of revenue $82.19 $87.47 $88.44 $92.84
Gross Profit $39.05 $33.06 $28.91 $29.61
Operating activities
Research & development $58.34 $63.82 $61.98 $71.53
Selling, general & administrative $83.62 $114.7 $89.75 $90.04
Total operating expenses $1019.24 $259.52 $204.28 $124.5
Operating income -$980.19 -$226.46 -$175.37 -$94.89
Income from continuing operations
EBIT -$942.43 -$201.41 -$181.65 -$90.57
Income tax expense -$6.17 -$0.92 -$0.96 -$5.35
Interest expense $5.85 $6.02 $11.5 $14.6
Net income
Net income -$942.11 -$206.51 -$192.18 -$99.82
Income (for common shares) -$942.11 -$206.51 -$192.18 -$99.82
(in millions $) 31 Dec 2022 31 Dec 2021 31 Dec 2020 31 Dec 2019
Revenue
Total revenue $516.3 $460.45 $279.6 $216.82
Cost of revenue $417.26 $348.67 $198.28 $118.1
Gross Profit $99.05 $111.78 $81.32 $98.72
Operating activities
Research & development $402.09 $416.09 $240.6 $141.53
Selling, general & administrative $411.19 $473.98 $492.89 $201.31
Total operating expenses $3219.31 $890.07 $733.5 $342.83
Operating income -$3120.26 -$778.29 -$652.17 -$244.11
Income from continuing operations
EBIT -$3094.45 -$365.96 -$684.5 -$248
Income tax expense -$44.9 -$36.86 -$112.1 -$18.45
Interest expense $56.75 $49.9 $29.77 $12.41
Net income
Net income -$3106.29 -$379.01 -$602.17 -$241.97
Income (for common shares) -$3106.29 -$379.01 -$602.17 -$241.97
(in millions $) 30 Sep 2023 30 Jun 2023 31 Mar 2023 31 Dec 2022
Net income -$942.11 -$206.51 -$192.18 -$99.82
Operating activities
Depreciation $34.37 $37.27 $38.07 $40.75
Business acquisitions & disposals $44.55
Stock-based compensation $26.13 $31.19 $30.02 $38.44
Total cash flows from operations -$66.89 -$54.91 -$34.4 -$82.03
Investing activities
Capital expenditures -$1.93 -$1.08 -$1.32 -$4.92
Investments $7.05 $117.15 $75.2 $82.26
Total cash flows from investing $5.12 $116.06 $73.88 $121.89
Financing activities
Dividends paid
Sale and purchase of stock -$0.06 $2.17 $0 $1.89
Net borrowings $0.73 -$1.29 -$134.3 -$1.23
Total cash flows from financing -$3.38 $0.88 -$135.77 $0.6
Effect of exchange rate
Change in cash and equivalents -$65.16 $62.03 -$96.29 $40.46
(in millions $) 31 Dec 2022 31 Dec 2021 31 Dec 2020 31 Dec 2019
Net income -$3106.29 -$379.01 -$602.17 -$241.97
Operating activities
Depreciation $152.31 $80.47 $39.05 $16.21
Business acquisitions & disposals $44.55 -$247.4 -$383.75 -$33.85
Stock-based compensation $207.73 $189.6 $249.77 $75.95
Total cash flows from operations -$492.96 -$559.82 -$298.5 -$145.05
Investing activities
Capital expenditures -$53.31 -$54.72 -$22.86 -$20.05
Investments -$166.05 $99.34 $10.06 -$226.42
Total cash flows from investing -$174.8 -$204.08 -$400.58 -$280.31
Financing activities
Dividends paid
Sale and purchase of stock $17.82 $458.03 $547.89 $213.49
Net borrowings -$5.41 $1112.67 $129.21 $252.19
Total cash flows from financing $1.76 $1565.94 $672.99 $464.77
Effect of exchange rate
Change in cash and equivalents -$666.01 $802.04 -$26.09 $39.41
Fundamentals
Market cap $3.21M
Enterprise value $1.34B
Shares outstanding 286.49M
Revenue $481.58M
EBITDA -$1.27B
EBIT -$1.42B
Net Income -$1.44B
Revenue Q/Q -9.21%
Revenue Y/Y -7.38%
P/E ratio -0.00
EV/Sales 2.79
EV/EBITDA -1.06
EV/EBIT -0.95
P/S ratio 0.01
P/B ratio -0.00
Book/Share -3.87
Cash/Share 0.59
EPS -$5.03
ROA -101.03%
ROE 472.72%
Debt/Equity 18.19
Net debt/EBITDA -1.15
Current ratio 2.39
Quick ratio 2.25